MTOR and osteosarcoma: For instance, Perry et al. identified recurrent mutations in the PI3K/mTOR (phosphatidylinositol-3-kinase/mammalian target of rapamycin) pathway in osteosarcomas, primarily through whole-exome sequencing (WES) [21].